Theravance Biopharma, Inc. Operating Lease, Liability, Noncurrent
Theravance Biopharma, Inc. (TBPH) had Operating Lease, Liability, Noncurrent of $27.77 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Noncurrent $27.77M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $29.75M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $31.76M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $33.68M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $27.77M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $29.75M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $31.76M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $33.68M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $35.56M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $37.35M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $39.11M 10-K · filed 2026-03-23 |
| 2024-09-30 | $40.78M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $42.44M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $43.84M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $45.24M 10-K · filed 2025-03-07 |
| 2023-09-30 | $41.12M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $42.52M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $43.76M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $45.41M 10-K · filed 2024-03-01 |
| 2022-09-30 | $51.38M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $50.64M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $47.41M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $52.68M 10-K · filed 2023-03-01 |
| 2021-09-30 | $54.35M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $57.77M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $57.03M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $47.22M 10-K · filed 2022-02-28 |
| 2020-09-30 | $47.82M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $47.63M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $47.20M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $47.73M 10-K · filed 2021-02-26 |
| 2019-09-30 | $48.62M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $48.56M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $48.49M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |